Recent Updates
Recently added Catalysts
TELO Positive Sentiment

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

Thursday, September 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Telomir Pharmaceuticals announced a peer-reviewed publication detailing preclinical research on Telomir-Zn. The study demonstrated significant improvements in visual function and retinal structure in a model of age-related macular degeneration (AMD). Additionally, it showed a reduction in mitochondrial oxidative stress, highlighting the potential of Telomir-Zn as a therapeutic option.

Market Sentiment Analysis

POSITIVE FACTORS

  • Telomir-Zn significantly improved visual function.
  • Restored retinal structure in AMD model.
  • Reduced mitochondrial oxidative stress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
7.3%
average across 3 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
Zn-Telomir
Phase 1 · Triple-Negative Breast Cancer (TNBC)

Full Press Release Details

MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD). The findings…
You can read the full content here
The post Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) appeared first on Telomir Pharmaceuticals, Inc. (TELO) .

Frequently Asked Questions

What is Telomir-Zn?

Telomir-Zn is a small-molecule therapeutic developed by Telomir Pharmaceuticals targeting AMD.

What were the findings of the Telomir-Zn study?

The study found that Telomir-Zn improved visual function and restored retinal structure in AMD models.

How does Telomir-Zn affect oxidative stress?

Telomir-Zn was shown to reduce mitochondrial oxidative stress in the AMD model.

Is the research on Telomir-Zn peer-reviewed?

Yes, the research on Telomir-Zn has been published in a peer-reviewed journal.

ShareAdd on Google
Tags: TELO Viatris Investor Conferences Healthcare Telomir Pharmaceuticals Telomir-Zn age-related macular degeneration AMD retinal structure
Last updated: Sep 17, 2026

Biotech snapshot

Cash runway
$5M liquidity · $0M/mo burn
~14 mo
Low dilution risk
Lead asset
Zn-TelomirPhase 1
Triple-Negative Breast Cancer (TNBC) →

Catalyst track record

+37%
best trade around TELO's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for TELO.

See every catalyst's timing & PoA →